Recent Updates
Recently added Catalysts

OCS-01- Dexamethasone Cyclodextrin Nanoparticle 1.5% mg/mL

Phase 2

Inflammation Corneal | Small molecule | Ophthalmology |Oculis Holding AG|Last Updated: Sep 9, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment153

FDA Designations

No designations recorded

Clinical trial landscape

OCS-01- Dexamethasone Cyclodextrin Nanoparticle 1.5% mg/mL · 1 trial · 2 indications

Phase 2 1
NCT04130802OCS-01 in Treating Inflammation and Pain in Post-cataract PatientsInflammation Corneal
COMPLETED153 Analytics
PHASE2COMPLETED
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Inflammation Corneal
NCT04130802153
Unlock trial analytics

Study Design & Arms

Interventions

NameTypeDescription
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mLDRUGOCS-01 eye drops
PlaceboDRUGVehicle eye drops
Unlock Study Design Details